Recommended

Discover how to understand pain pathways and accelerate the search for next-generation analgesics – register today
LAST CHANCE TO REGISTER | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
NEW REPORT | Explore how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
The scientific advances driving cancer drug discovery – find out more
Meet the precision peptide changing how we study pain
news

BenevolentAI hires new head of Cheminformatics from The Institute of Cancer Research

BenevolentAI announced today it has hired Dr Nathan Brown, as its new Head of Cheminformatics following the promotion of Mark Davies…

Cheminformatics

BenevolentAI announced today it has hired Dr Nathan Brown BSc (Hons) FRSC, as its new Head of Cheminformatics following the promotion of Mark Davies from Head of Cheminformatics to Vice President of Biomedical Informatics earlier in the year.  

Dr Brown joined the Institute of Cancer Research (ICR), London in 2007 where he founded and led the new In Silico Medicinal Chemistry Group which focused on medicinal chemistry research towards novel cancer treatments. Dr Brown holds a degree in computing from Robert Gordon University, Aberdeen and conducted his doctoral research in the field of Cheminformatics at the University of Sheffield.  Following his PhD he was awarded a Marie Curie Fellowship for two years working with Avantium in Amsterdam and subsequently one of the first to be awarded a prestigious Presidential Research Fellowship for three years, by Professor Mark Fishman, Global Head of Research at the Novartis Institutes for BioMedical Research.

With extensive experience as a software designer Dr Brown has developed many novel algorithms to maximise the impact of the experimental data generated in medicinal chemistry and cancer biology. Furthermore Dr Brown is a recent recipient of the Corwin Hansch Award for contributions to computational chemistry. 

 

access your free copy

 


Biomarkers are redefining how precision therapies are discovered, validated and delivered. 

This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Inside the report:

  • How leading organisations are reshaping strategy with biomarker-led approaches
  • Better tools for real-time decision-making – turning complex data into faster insights
  • Global standardisation and assay sensitivity – what it takes to scale across networks

Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today

 

Jackie Hunter, CEO of Benevolent Bío, the bioscience subsidiary of BenevolentAI, commented

“Nathan Brown is a recognised leader in the field of cheminformatics, molecular informatics and computational chemistry.  He has done exceptional work in the development of innovative anti-cancer therapies in an academic setting and his work is respected and well published.  We are delighted to have Nathan on board.”